MGNXMACROGENICS INC

Nasdaq macrogenics.com


$ 4.46 $ -0.21 (-4.49 %)    

Friday, 14-Jun-2024 15:59:56 EDT
QQQ $ 479.30 $ 2.47 (0.52 %)
DIA $ 386.46 $ -0.42 (-0.11 %)
SPY $ 542.65 $ 0.33 (0.06 %)
TLT $ 94.67 $ 0.79 (0.84 %)
GLD $ 215.76 $ 2.76 (1.3 %)
$ 4.47
$ 4.64
$ 4.01 x 101
$ 4.47 x 399
$ 4.43 - $ 4.64
$ 3.14 - $ 21.88
1,011,747
na
278.44M
$ 1.80
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-07-2024 12-31-2023 10-K
3 11-06-2023 09-30-2023 10-Q
4 08-09-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 03-15-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-03-2022 03-31-2022 10-Q
10 02-24-2022 12-31-2021 10-K
11 11-02-2021 09-30-2021 10-Q
12 07-29-2021 06-30-2021 10-Q
13 04-29-2021 03-31-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 11-04-2020 09-30-2020 10-Q
16 07-31-2020 06-30-2020 10-Q
17 05-05-2020 03-31-2020 10-Q
18 02-25-2020 12-31-2019 10-K
19 11-06-2019 09-30-2019 10-Q
20 07-31-2019 06-30-2019 10-Q
21 05-01-2019 03-31-2019 10-Q
22 02-26-2019 12-31-2018 10-K
23 11-07-2018 09-30-2018 10-Q
24 08-07-2018 06-30-2018 10-Q
25 05-07-2018 03-31-2018 10-Q
26 02-27-2018 12-31-2017 10-K
27 11-08-2017 09-30-2017 10-Q
28 08-02-2017 06-30-2017 10-Q
29 05-03-2017 03-31-2017 10-Q
30 02-28-2017 12-31-2016 10-K
31 11-02-2016 09-30-2016 10-Q
32 08-03-2016 06-30-2016 10-Q
33 05-04-2016 03-31-2016 10-Q
34 02-29-2016 12-31-2015 10-K
35 11-04-2015 09-30-2015 10-Q
36 08-05-2015 06-30-2015 10-Q
37 05-06-2015 03-31-2015 10-Q
38 03-03-2015 12-31-2014 10-K
39 11-12-2014 09-30-2014 10-Q
40 08-05-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 btig-maintains-buy-on-macrogenics-lowers-price-target-to-9

BTIG analyst Kaveri Pohlman maintains Macrogenics (NASDAQ:MGNX) with a Buy and lowers the price target from $24 to $9.

 hc-wainwright--co-maintains-neutral-on-macrogenics-lowers-price-target-to-4

HC Wainwright & Co. analyst Robert Burns maintains Macrogenics (NASDAQ:MGNX) with a Neutral and lowers the price target ...

 barclays-maintains-overweight-on-macrogenics-lowers-price-target-to-14

Barclays analyst Peter Lawson maintains Macrogenics (NASDAQ:MGNX) with a Overweight and lowers the price target from $25 to ...

 macrogenics-gets-downgraded-following-disappointing-prostate-cancer-trial-results-we-were-surprised-by-reported-deaths

Despite MacroGenics' clinical activity, unexpected adverse events raise concerns. Analysts adjust ratings and price targets.

 stocks-pause-on-dismal-consumer-confidence-yields-dollar-rise-as-inflation-expectations-kick-higher-bitcoin-sinks-whats-driving-markets-friday-corrected

Editor’s note: This story has been updated to correct an error in the price action of Charter Communications stock.

 jmp-securities-maintains-market-outperform-on-macrogenics-lowers-price-target-to-16

JMP Securities analyst Silvan Tuerkcan maintains Macrogenics (NASDAQ:MGNX) with a Market Outperform and lowers the price tar...

 bmo-capital-downgrades-macrogenics-to-market-perform-lowers-price-target-to-8

BMO Capital analyst Etzer Darout downgrades Macrogenics (NASDAQ:MGNX) from Outperform to Market Perform and lowers the price...

 macrogenics-shares-tumble-after-reporting-adverse-events-multiple-deaths-in-cancer-drug-trial

Latest interim data from TAMARACK Phase 2 study by MacroGenics unveils insights into vobramitamab duocarmazine targeting B7-H3 ...

 td-cowen-downgrades-macrogenics-to-hold

TD Cowen analyst Boris Peaker downgrades Macrogenics (NASDAQ:MGNX) from Buy to Hold.